ArticleJournal of cardiology cases2026
Thrombocytosis-associated ticagrelor non-responder status after ECMO-supported primary PCI in STEMI.
Article in Journal of cardiology cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite established treatment pathways for ST-elevation myocardial infarction (STEMI), complications range from adverse events such as malignant cardiac arrhythmias to more elusive risks such as thrombocytosis compromising antiplatelet efficacy. We describe a case of ticagrelor non-responsiveness in a patient who developed critical reactive thrombocytosis after veno-arterial extracorporeal membrane oxygenation-supported percutaneous coronary intervention for inferior STEMI. High on-treatment platelet reactivity was detected by Multiplate (Roche Diagnostics, Mannheim, Germany) testing at a time when the platelet count exceeded 1.1 × 10 Learning objective: Ticagrelor may present a pharmacodynamic challenge in patients with thrombocytosis. In very high-risk patients, particularly those with atypical hematologic profiles, verifying the efficacy of platelet aggregation inhibition through laboratory testing is essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.